Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease

The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis despite the drug’s loss to Sanofi’s Avapro in a Phase 3 study.